Literature DB >> 3937546

T cell differentiation antigens expressed by peripheral blood lymphocytes in Crohn's disease.

F Pallone, O Squarcia, S Fais, M Boirivant, L Biancone, G Tonietti.   

Abstract

The aim of the present study was to investigate whether an imbalance of peripheral blood immunoregulatory T cells is a feature of Crohn's disease. The cluster of differentiation antigens 3,4 and 8 were investigated and the relative prevalence of PBL expressing each antigen was defined using a panel of three monoclonal antibodies (OKT3, OTK4 and OKT8). A significant decrease in the OKT3 and OKT4 positive cells was found in CD patients as compared with healthy controls. No significant difference was observed between patients and controls in the proportion of T8 positive cells and in the T4/T8 ratio. While confirming a significant decrease of circulating total resting T cells in patient with CD, the results of this study indicate that the disease is not primarily related to an imbalance of the proportion of the T cells subsets.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3937546

Source DB:  PubMed          Journal:  Boll Ist Sieroter Milan        ISSN: 0021-2547


  3 in total

1.  Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens.

Authors:  F Pallone; S Fais; O Squarcia; L Biancone; P Pozzilli; M Boirivant
Journal:  Gut       Date:  1987-06       Impact factor: 23.059

2.  Serum immunomodulatory factors in gastrointestinal diseases. A 30-50-kD serum fraction in Crohn's disease capable of modulating lymphocyte activation.

Authors:  L Biancone; M Boirivant; S Fais; G L Ricci; R Paganelli; F Pallone
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

Review 3.  Crohn's disease and the mycobacterioses: a review and comparison of two disease entities.

Authors:  R J Chiodini
Journal:  Clin Microbiol Rev       Date:  1989-01       Impact factor: 26.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.